Status:
COMPLETED
Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis
Lead Sponsor:
Catholic University of the Sacred Heart
Conditions:
Coronary Artery Disease
Coronary Stenosis
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
BACKGROUND: Bifurcated lesions are a challenging subset in percutaneous coronary interventions (PCI). The selection of the type of drug-eluting stents (DES) and the technique for stent implantation h...
Detailed Description
Bifurcated lesions are challenging target lesions in percutaneous coronary interventions (PCI) which may specifically benefit from the usage of drug-eluting stents (DES). However, the selection of the...
Eligibility Criteria
Inclusion
- de novo bifurcated lesions
- lesions \>50% located in a major bifurcation point
- TIMI \>2 on both main vessel and side branch
- main vessel visual diameter \>2.5 mm
- side branch visual diameter \>2.0 mm
- \>18 years of age
- signed the informed consent to enter the study
Exclusion
- known hypersensitivity to Sirolimus, Everolimus, cobalt, chromium, nickel, tungsten acrylic and fluoro-polymers
- contraindications to double antiplatelet therapy acute (within 48 hours) ST-elevation acute myocardial infarction
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01200693
Start Date
November 1 2008
End Date
March 1 2012
Last Update
February 15 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Cardiology - Catholic University of Sacred Heart
Rome, Italy, 00100